The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinomas: Relationship with CT Characteristics and Histologic Subtypes
Abstract
PURPOSE: To retrospectively identify quantitative computed tomographic (CT) features that correlate with epidermal growth factor receptor (EGFR) mutation in surgically resected lung adenocarcinomas stratified by the International Association for the Study of Lung Cancer (IASLC), American Thoracic Society (ATS), and European Respiratory Society (ERS) classification in an East Asian cohort of patients known to have a high prevalence of EGFR mutations. MATERIALS AND METHODS: An institutional review board approved this study and waived informed consent. In 153 surgically resected lung adenocarcinomas, EGFR mutation was determined by direct DNA sequencing. Histologic subtype was classified according to IASLC/ATS/ERS classification of lung adenocarcinoma. At preoperative chest CT, the percentage of ground-glass opacity (GGO) volume and total tumor volume of each tumor were measured by using a semiautomated algorithm. Distribution of EGFR mutation according to histologic subtype, percentage of GGO volume, and total tumor volume was evaluated by using the Fisher exact test, the Student t test, trend analysis, and multiple logistic regression analysis. RESULTS: Exon 21 missense mutation was more frequent in lepidic predominant adenocarcinomas than in other histologic subtypes (odds ratio, 3.44; 95% confidence interval: 1.53, 7.74; P = .003). GGO volume percentage in tumors with exon 21 missense mutation (61.7% ± 31.9 [standard deviation]) was significantly higher than that in EGFR wild-type tumors (30.0% ± 38.5) (P = .0001) and exon 19-mutated tumors (28.9% ± 37.7) (P = .0006). A significant trend of prevalence of exon 21 missense mutation increasing along with increasing GGO volume (P = .0008) was found. CONCLUSION: GGO volume percentage in tumors with exon 21 missense mutation was significantly higher than that in tumors with other EGFR mutation status. This can be related to the fact that exon 21 missense mutation was significantly more frequent in lepidic predominant adenocarcinomas, including adenocarcinoma in situ, minimally invasive adenocarcinoma, and lepidic predominant invasive adenocarcinoma, according to IASLE/ATS/ERS classification.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Cancer Incidence in Five Continents
(1966) · doi:10.1007/978-3-642-85849-9 · Cited by 5,936
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Cited by
Intrinsic dependencies of CT radiomic features on voxel size and number of gray levels
Shafiq‐ul‐Hassan, M., Zhang, G. G., Latifi, K., Ullah, G., Hunt, D. C., Balagurunathan, Y., Abdalah, M. A., Schabath, M. B., Goldgof, D. G., Mackin, D., et al. (2017) · Medical Physics · doi:10.1002/mp.12123 · Cited by 585
Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas
Liu, Y., Kim, J., Balagurunathan, Y., Li, Q., Garcia, A. L., Stringfield, O., Ye, Z., & Gillies, R. J. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.02.001 · Cited by 318
CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer
Rizzo, S., Petrella, F., Buscarino, V., De Maria, F., Raimondi, S., Barberis, M., Fumagalli, C., Spitaleri, G., Rampinelli, C., De Marinis, F., et al. (2016) · European Radiology · doi:10.1007/s00330-015-3814-0 · Cited by 270
Identification of non-small cell lung cancer sensitive to systemic cancer therapies using radiomics
Dercle, L., Fronheiser, M., Lu, L., Du, S., Hayes, W., Leung, D. K., Roy, A., Wilkerson, J., Guo, P., Fojo, A. T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2942 · Cited by 177
Self-citationPredictive radiogenomics modeling of EGFR mutation status in lung cancer
Gevaert, O., Echegaray, S., Khuong, A., Hoang, C. D., Shrager, J. B., Jensen, K. C., Berry, G. J., Guo, H. H., Lau, C., Plevritis, S. K., et al. (2017) · Scientific Reports · doi:10.1038/srep41674 · Cited by 160
Metadata
- Authors
- Lee, H.-J., Kim, Y. T., Kang, C. H., Zhao, B., Tan, Y., Schwartz, L. H., Persigehl, T., Jeon, Y. K., & Chung, D. H.
- Venue
- Radiology
- Published
- 2013-07
- Volume
- 268
- Issue
- 1
- Pages
- 254-264
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- OpenAlex
- W2140124489
- Cited by
- 176
- References
- 5
- FWCI
- 11.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinomas: Relationship with CT Characteristics and Histologic Subtypes. https://app.cochat.ai/papers/10.1148/radiol.13112553
- The paper
- Lee, H.-J., Kim, Y. T., Kang, C. H., Zhao, B., Tan, Y., Schwartz, L. H., Persigehl, T., Jeon, Y. K., & Chung, D. H. (2013). Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinomas: Relationship with CT Characteristics and Histologic Subtypes. Radiology. https://doi.org/10.1148/radiol.13112553
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.